2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

637. Myelodysplastic Syndromes: Clinical and Epidemiological

Program: Oral Abstract Session
Monday, December 14, 2026
10:30 a.m. - 12:00 p.m.
MCCNO - Great Hall AD
Technology and Procedures, Molecular Testing, Omics Technologies, Biological Processes, CHIP, Genomics, Hematopoiesis, Molecular Biology, Diseases, Bone Marrow Failure Syndromes, Inherited Marrow Failure Syndromes, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, AML, Translational Research, MDS, MPN, CMML, Clinical Research, Clinical Trials, Study Population, Human, Animal Model
PAPER

808 Obesity promotes clonal myeloid progression and is attenuated by GLP-1 receptor agonism

Joshua Weinreb, MD, PhD, J. Scott Austin Beeler, MD, PhD2, Pu Zhang3, Irenaeus Chi-Chung Chan, M.Sc.4, Kevin Watanabe-Smith, PhD5, Andriy Derkach, PhD6, Cynthia Castro7, Steven Tittley8, Nicola Long9, Christina Zheng10, Yongmei Chen11, Yong Lin12, Erica Johnston13, Jeffrey Tyner, PhD14, Eytan M Stein I, MD15, Kelly Bolton, MD, PhD16, Omar Abdel-Wahab, MD17
1 Memorial Sloan Kettering Cancer Center, New York, New York, United States
2 Washington University in Saint Louis, Saint Louis, Missouri, United States
3 Memorial Sloan Kettering Cancer Center, New York, New York, United States
4 Washington University in Saint Louis, Saint Louis, Missouri, United States
5 OHSU Knight Cancer Institute Pharmacy Beaverton, Beaverton, Oregon, United States
6 Memorial Sloan Kettering Cancer Center, New York, New York, United States
7 Memorial Sloan Kettering Cancer Center, New York, New York, United States
8 Memorial Sloan Kettering Cancer Center, New York, New York, United States
9 OHSU Knight Cancer Institute Pharmacy Beaverton, Beaverton, Oregon, United States
10 OHSU Knight Cancer Institute Pharmacy Beaverton, Beaverton, Oregon, United States
11 Eli Lilly, Indianapolis, Indiana, United States
12 Eli Lilly, Indianapolis, Indiana, United States
13 Eli Lilly, Indianapolis, Indiana, United States
14 OHSU Knight Cancer Institute Pharmacy Beaverton, Beaverton, Oregon, United States
15 Memorial Sloan Kettering Cancer Center, New York, New York, United States
16 Washington University in Saint Louis, Saint Louis, Missouri, United States
17 Memorial Sloan Kettering Cancer Center, New York, New York, United States, Memorial Sloan Kettering Cancer Center, New York, New York, United States

Obesity is a prevalent, modifiable inflammatory state associated with increased risk of myeloid malignancy, but its relationship to clonal hematopoiesis (CH), MDS progression, AML biology, and therapeutic interception in these conditions remain incompletely defined. GLP-1 receptor agonists (GLP-1RA) induce weight loss and have anti-inflammatory effects, raising the possibility that they may alter obesity-associated clonal myeloid progression. Here we integrated population-level, clinical, transcriptional, pharmacoepidemiologic, and in vivo studies to identify that obesity is associated with adverse outcomes across the continuum of CH, MDS, and AML while GLP-1RA exposure is associated with reduced obesity-driven Tet2-mutant clonal expansion in mice and MDS progression to AML in patients.

We first tested associations between adiposity, CH mutational classes, and subsequent myeloid malignancy in the UK Biobank. In this cohort, waist-to-hip ratio (WHR), a measure of central adiposity, was associated with CH, with the strongest associations observed for DNA damage repair and splicing factor CH, mutational classes linked to increased myeloid neoplasm risk. WHR was also associated with subsequent myeloid malignancy development, and CH prevalence increased progressively across sex-specific WHR quartiles and BMI categories, supporting a graded relationship between adiposity and high-risk CH.

Next, in a cohort of 1246 patients with MDS, including 930 with BMI at diagnosis, we assessed associations between obesity and clinical outcomes. In this cohort of patients with MDS, obesity was associated with inferior overal survival (OS) (mOS 43.1 vs NR months; HR 1.57, 95% CI 1.19-2.07; P=0.001), leukemia-free survival (LFS; p=0.01), and enrichment for adverse disease features, including higher IPSS-M/IPSS-R scores, higher mutation count, increased marrow blasts, and lower platelets. Nearly all deaths with available attribution were related to MDS, MDS complications, or AML progression. Finally, using a cohort of BEAT AML patients with associated BMI data, obesity was also associated with inferior OS though it did not reach statistical significance (mOS 16.0 vs 28.3 months; HR 1.43, 95% CI 0.98-2.08; P=0.0645).

Given these associations between obesity and progression of CH and MDS, we used a target trial emulation framework in TriNetX and Optum Market Clarity to evaluate whether GLP-1RA exposure was associated with a lower risk of MDS progression to AML. Across these datasets, GLP-1RA exposure was consistently associated with reduced AML progression after MDS. In TriNetX, an EMR database, GLP-1RA exposure within 3 years of MDS diagnosis was compared with non-GLP-1RA diabetes medications after propensity score matching. 779 patients were included per group, and GLP-1RA exposure was associated with reduced AML progression (HR 0.68, 95% CI 0.49-0.93; P=0.016). Results were directionally consistent versus metformin (HR 0.67) and SGLT2 inhibitors (HR 0.80). In Market Clarity, a claims-based database, GLP-1RA exposure (n=999 patients per group) was independently associated with lower AML progression after negative control outcome calibration (competing-risk subdistribution HR 0.39, 95% CI 0.22-0.68).

In murine models of myeloid malignancy, high-fat diet increased Tet2-deficient clonal contribution in bone marrow and spleen, increased LT-HSC abundance, and altered granulocytic output. Semaglutide attenuated obesity-driven Tet2-mutant clonal expansion and reduced diet-associated granulocytic skewing. Consistent with this model, adiposity in UK Biobank was strongly associated with circulating CRP and monocytosis and obesity was associated with increased inflammatory signaling, including enrichment of interferon-a, TNF/NF-κB, complement, and IL2/STAT5 signaling, as well as a corresponding shift towards more differentiated pro-monocytic tumor cell state in the BEAT AML cohort.

Obesity is associated with high-risk CH, adverse outcomes across MDS and AML, systemic inflammation, myeloid skewing, and inflammatory AML transcriptional states. GLP-1RA exposure is associated with reduced AML progression in MDS, with effects more pronounced than with either metformin or SGLT2 inhibitors, and semaglutide markedly attenuated obesity-driven Tet2-mutant clonal expansion in vivo. These findings identify obesity-associated inflammation as a modifiable driver of myeloid clonal progression and support prospective GLP-1RA interception trials in MDS and high-risk CH.

Joshua Weinreb, MD, PhD: No relevant conflicts of interest to declare.